Online citations, reference lists, and bibliographies.
← Back to Search

Combination And Monotherapy With Zidovudine And Zalcitabine In Patients With Advanced HIV Disease

M. Fischl, K. Stanley, A. Collier, J. Arduino, D. Stein, J. Feinberg, J. Allan, J. Goldsmith, W. Powderly
Published 1995 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Several nucleoside analogs, including zidovudine, zalcitabine, and didanosine, inhibit the replication of human immunodeficiency virus type 1 (HIV) in vitro and improve CD4 cell counts and suppress HIV p24 antigenemia in patients with HIV disease [1-8]. Zidovudine therapy delays HIV disease progression [1-3] and improves survival in patients with advanced HIV disease [1, 9]. Didanosine therapy delays HIV disease progression in patients with advanced HIV disease who had previously received zidovudine, suggesting that switching antiretroviral therapy may be an important strategy in treating HIV disease [10, 11]. The combination of the nucleoside analogs zidovudine and zalcitabine has additive to synergistic inhibitory activity against HIV in vitro, and viral isolates resistant to zidovudine remain susceptible to zalcitabine in vitro [12-14]. Combination therapy with zidovudine and zalcitabine causes a greater and more sustained increase in CD4 cell counts and suppression of HIV p24 antigenemia than does either drug used alone in patients with advanced HIV disease who have not previously received therapy with zidovudine or zalcitabine [15]. The clinical correlation of these findings is unknown. These observations prompted us to try to determine whether zalcitabine monotherapy or combination therapy with zidovudine and zalcitabine would improve clinical outcome in patients with advanced HIV disease who had previously received zidovudine. Methods Study Sample The study sample consisted of patients with symptomatic HIV disease who had a CD4 cell count of 300 cells/mm3 or less or patients with asymptomatic HIV disease who had a CD4 cell count of 200 cells/mm3 or less. Participants had previously received and tolerated at least 6 months of zidovudine treatment. The eligibility criteria also included a hemoglobin concentration of 92 g/L or more, a neutrophil count of 1.0 109/L or more, a platelet count of 75 109/L or more, serum alanine aminotransferase and aspartate aminotransferase levels no higher than five times the upper range of normal, Karnofsky performance status of 60 or more, and positive results of serum tests for HIV antibody. We excluded patients with a history of intolerance to zidovudine at a dose of 600 mg/d or less, previous zalcitabine therapy, mild or more severe peripheral neuropathy, or Kaposi sarcoma requiring systemic therapy; women of childbearing age who were pregnant or breast-feeding were also excluded. We accepted patients receiving chemoprophylaxis for Pneumocystis carinii pneumonia, candidiasis and herpes simplex virus infection, and those receiving erythropoietin and granulocyte colony-stimulating factor. We excluded persons taking other antiretroviral drugs, biological response modifiers, cytotoxic chemotherapy, drugs other than isoniazid that cause peripheral neuropathy, or investigational drugs. We recruited patients from 35 AIDS Clinical Trials Units and 16 National Hemophilia Foundation sites between December 1990 and August 1991. The study was approved by the institutional review board at each institution, and patients gave written informed consent. Study Design and Treatment Regimen The study was a multicenter, randomized, double-blind clinical trial that compared the safety and efficacy of zidovudine, zalcitabine, and the combination of zidovudine and zalcitabine. Randomization was weighted at 2:2:3, favoring the combination group. Patients were stratified by HIV disease status (symptomatic or asymptomatic), by duration of previous zidovudine therapy ( 1 year or >1 year), and by P. carinii pneumonia chemoprophylaxis regimen (systemic therapy, nonsystemic therapy, both, or neither). Zalcitabine (Hivid; Hoffmann-La Roche, Inc., Nutley, New Jersey) was given in two 0.375-mg tablets every 8 hours. Zidovudine (Retrovir; Burroughs Wellcome Co., Research Triangle Park, North Carolina) was given in two 100-mg capsules every 8 hours. The primary end point for the study was time to an acquired immunodeficiency syndrome (AIDS)-defining event or death, whichever occurred first. All end points were reviewed in a blinded manner by the study chairpersons. Patients continued to receive blinded study medication after the development of a primary study end point. The protocol was modified on 20 March 1992 to allow patients who had reached a primary study end point the option to cross over to open-label combination therapy. Secondary end points included survival, CD4 cell count changes, and decreased HIV p24 antigenemia. Management of Toxic Effects All study medications were interrupted, regardless of whether the toxicity was believed to be associated with either zidovudine or zalcitabine, in patients in whom a moderate or severe peripheral neuropathy or another severe or worse toxic effect developed. Once the toxicity grade returned to pretreatment values or a lower grade, study medications were restarted at one half the initial dose. Study medications were permanently discontinued in patients who had a recurrent moderate or severe peripheral neuropathy or another severe or worse toxic effect within a 30-day period. Patients who had recurrent toxic effects after more than 30 days, except for those with peripheral neuropathy, continued to receive study medications once the toxicity grade returned to a lower grade or to pretreatment values. Patient Evaluation Patients were evaluated at weeks 0, 4, 8, and 12, and every 8 weeks thereafter. The CD4 cell counts were measured within 60 days before study enrollment, at weeks 0, 2, and 4, every 4 weeks until week 52, and every 8 weeks thereafter. Blood for HIV p24 antigen determinations was collected at weeks 0, 2, 4, 8, 12, 24, 36, 48, and 60 and every 16 weeks thereafter. Determinations of HIV p24 antigen were done simultaneously on stored serum aliquots by an enzyme-linked immunosorbent assay (Abbott Laboratories, North Chicago, Illinois). A positive assay result was one that detected an antigen level of 25 pg/mL or more. Laboratories measuring CD4 cell counts and serum p24 antigen levels had to meet the performance-monitored standards of the AIDS Clinical Trials Group. Statistical Analysis We assessed differences in proportions using the Fisher exact test. Time-to-event distributions were estimated using the Kaplan-Meier method and compared using the log-rank test and Cox proportional-hazards model [16], with stratification for HIV disease status, duration of previous zidovudine therapy, and P. carinii pneumonia prophylaxis [17]. Analyses were based on an intention-to-treat approach [18]. We censored data on toxic effects 30 days after crossover or discontinuation of study medications. We used the hazard ratios, expressed as relative risk, and 95% two-sided confidence intervals. All P values were two-sided and were not adjusted for multiple comparisons. A test of trend evaluating the interaction between pretreatment CD4 cell counts and treatment effect on the primary end point was based on Cox models and included the study stratification factors as covariates and pretreatment CD4 cell counts as a continuous variable. For completeness, two additional tests of trend used stratified Cox models in which pretreatment CD4 cell counts were modeled as a categorical variable. In one analysis, pretreatment CD4 cell count was modeled as a binary variable, above and below the median CD4 cell count (119 cells/mm3). In a second analysis, pretreatment CD4 cell count was modeled as a discrete variable with three levels ( 1,0, 1) corresponding to the three planned CD4 cell subgroups. Changes in CD4 cell counts and serum HIV p24 antigen levels were expressed as the percentage change from pretreatment values for each patient. Trends in CD4 cell counts over time were evaluated by estimating the slopes from pretreatment to the time of aggregate peak (week 2) and separately estimating the slopes for subsequent time points. We compared the slopes using nonparametric tests [19]. We also analyzed treatment differences for patients with pretreatment CD4 cell counts of less than 50 cells/mm3, 50 to 150 cells/mm3, and 150 cells/mm3 or greater. The three CD4 cell count subgroups were specified by the study chairpersons in June 1992, which was before any interim review of the primary end-point data and unblinding to the study results by the study chairpersons (March 1993). The three CD4 cell count subgroups were chosen based on documented associations between CD4 cell counts and survival and development of zidovudine resistance. Results Study Sample We enrolled 1001 patients in the study between December 1990 and August 1991. No patients were ineligible for the study, except for those granted an exemption by the study chairpersons. We excluded 10 patients from the analyses: 7 who never received study medications and were not followed and 3 who were lost to follow-up within the first 2 weeks of treatment. The patients included 888 (90%) men and 103 (10%) women; their median age was 37 years. Overall, 809 patients (82%) were white, 152 (15%) were black, and 3% were neither; 117 (12%) were Hispanic and 884 (88%) were non-Hispanic. Eight hundred nineteen (83%) patients had symptomatic HIV disease. The median duration of previous zidovudine therapy was 18 months. The median pretreatment CD4 cell count was 119 cells/mm3, and 254 of 925 patients had detectable levels of serum HIV p24 antigen ( 25 pg/mL) before treatment. The treatment groups were well balanced with regard to pretreatment characteristics (Table 1). Table 1. Patient Characteristics by Treatment Group* We randomly assigned 283 patients to the zidovudine group, 285 to the zalcitabine group, and 423 to the combination group. Three hundred eighty-six patients had 150 or more CD4 cells/mm3, 336 had 50 to 150 CD4 cells/mm3, and 269 had fewer than 50 CD4 cells/mm3. Overall, the treatment groups within each CD4 cell subgroup were well balanced with regard to pretreatment characteristics (data not shown). The median duration of foll
This paper references
10.2307/2344557
Nonparametric Statistical Methods.
M. Knott (1974)
10.2307/2987660
Clinical Trials: A Practical Approach
S. Pocock (1984)
10.1056/NEJM198707233170401
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
M. Fischl (1987)
10.1016/S0140-6736(88)90283-8
PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)
R. Yarchoan (1988)
10.7326/0003-4819-110-3-189
Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study.
T. Merigan (1989)
10.1126/SCIENCE.2502840
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.
R. Yarchoan (1989)
10.1128/AAC.34.3.436
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.
B. Larder (1990)
10.1056/NEJM199005103221902
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
T. Cooley (1990)
10.7326/0003-4819-112-10-727
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial
M. Fischl (1990)
10.1056/NEJM199004053221401
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
P. Volberding (1990)
10.1056/NEJM199005103221901
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
J. Lambert (1990)
2',3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine.
Y. Törnevik (1990)
10.1001/JAMA.1992.03480090080031
Survival of Zidovudine-Treated Patients With AIDS Compared With That of Contemporary Untreated Patients
S. Vella (1992)
10.7326/0003-4819-116-1-13
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
T. Meng (1992)
10.1056/NEJM199208273270901
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
J. Kahn (1992)
10.1128/AAC.36.7.1559
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro
J. Eron (1992)
A controlled trial comparing continued zidovudine with di- danosine in human immunodeficiency virus infection
JO Kahn (1992)
10.7326/0003-4819-118-9-199305010-00004
Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS
M. Koot (1993)
10.7326/0003-4819-118-10-199305150-00002
Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy
M. Fischl (1993)
10.7326/0003-4819-119-6-199309150-00034
Pancreatitis Possibly Related to 2-3-Dideoxycytidine
S. L. Aponte-Cipriani (1993)
Safety and tolerance of zalcitabine (ddC, HIVID) in a double-blind, comparative trial (ACTG 114; N3300)
R Scott (1993)
10.1093/INFDIS/169.5.968
The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression.
D. Richman (1994)
10.1001/ARCHINTE.1995.00430090111012
Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine
R. Dolin (1995)
Regression Models and Life-Tables
D.



This paper is referenced by
10.1080/17512433.2020.1782737
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
A. Giacomelli (2020)
10.1093/infdis/jiz632
New perspectives on the virologic consequences of M184V or I in HIV-1 Reverse Transcriptase.
D. Kuritzkes (2019)
SIMPLE SPECTROPHOTOMETRIC ASSAY AND BIOLOGIACL EVALUATION OF ZALCITABINE
V. L. Janardhana Reddy (2017)
10.1182/blood-2016-10-741207
Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
Sanduni U. Liyanage (2017)
10.4103/2045-080X.181036
Safety profile of antiretroviral therapy: An urgent need for monitoring
D. Bhandari (2016)
10.6084/M9.FIGSHARE.1355781.V1
Comparative Study Of Adverse Drug Reactions Of Two Antiretroviral Regimens (Zidovudine+ Lamivudine + Nevirapine Vs Stavudine+ Lamivudine+ Nevirapine) In Hiv/Aids Patients
Iosr Journals (2015)
10.1002/9781118445112.stat04969
Treatment-Covariate Interaction †
D. Dixon (2014)
10.1002/9781118445112.STAT00261
Clinical Trials ‐ Further Developments
R. Simon (2014)
10.2165/00019053-199610020-00001
Current Controversies in the Treatment of HIV Infection and AIDS
S. Petrou (2012)
10.2165/00003495-199855030-00005
Antiretroviral Therapy for HIV Infection
G. Moyle (2012)
Adherence to anti-retroviral therapy in the federal capital territory, Abuja, Nigeria
Y. Avong (2012)
10.2165/00003495-199500491-00008
Combination Antiretroviral Therapy
J. Lange (2012)
10.2165/00003495-199500491-00005
Early Versus Delayed Treatment of HIV Infection
D. Richman (2012)
10.1590/S0037-86822011000100009
Impacto do tratamento antirretroviral na ocorrência de macrocitose em pacientes com HIV/AIDS do município de Maringá, Estado do Paraná
Odete Correia Antunes de Oliveira (2011)
Virologic failure and HIV-1 drug resistance among antiretroviral therapy recipients in an urban resource-limited setting - the South African Virologic Evaluation (SAVE) study
Z. El-Khatib (2011)
10.1016/B978-0-7020-4064-1.00043-9
CHAPTER 43 – Antiretroviral therapy for HIV
A. Pozniak (2010)
10.1016/B978-0-443-06839-3.00128-4
Antiretroviral Therapy for Human Immunodeficiency Virus Infection
A. Tsibris (2010)
10.1016/S0001-7310(09)70819-1
Reacciones cutáneas adversas a fármacos en los pacientes con infección por el VIH en la era TARGA
M. Blanes (2009)
10.1016/S1578-2190(09)70062-9
[Cutaneous drug reactions in HIV-infected patients in the HAART era].
M. Blanes (2009)
10.1007/978-0-387-77976-8_8
Acquired Immune Deficiency Syndrome
M. Khan (2008)
10.11606/T.5.2008.TDE-08072008-133201
Aids, tecnologia e acesso sustentável a medicamentos: a incorporação dos anti-retrovirais no Sistema Único de Saúde
M. Scheffer (2008)
10.1007/BF02705115
The chemical bases of the various AIDS epidemics: Recreational drugs, anti-viral chemotherapy and malnutrition
P. Duesberg (2007)
10.2310/6620.2007.05041
Adverse Cutaneous Reactions to Antimicrobials in Patients with Human Immunodeficiency Virus Infection
Daniel D. Miller (2007)
10.1016/J.CCT.2005.08.003
The use of unequal randomisation ratios in clinical trials: a review.
J. Dumville (2006)
10.1007/978-1-59745-085-0_3
Stavudine, Didanosine, and Zalcitabine
G. Skowron (2006)
10.1124/PR.58.3.10
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
T. Chou (2006)
10.1007/978-0-387-31047-3_7
New concepts in anti-HIV therapies
J. Stebbing (2006)
10.1007/978-1-59745-085-0_8
Peripheral Neuropathy Associated With Nucleoside Reverse Transcriptase Inhibitor Therapy
B. A. Cohen (2006)
10.1016/S0755-4982(05)84227-7
Effets indésirables induits par les traitements antirétroviraux
M. Lagrange-Xelot (2005)
10.1002/0470011815.B2A01058
Treatment‐Covariate Interaction
D. O. Dixon (2005)
10.1023/A:1007400519792
Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystic carinii Pneumonia (PCP) before AIDS diagnosis in Italy
P. Napoli (2004)
10.1007/978-3-0348-7869-2_2
A perspective of the history of HAART
D. Konopnicki (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar